Mergers & Acquisitions
Filter News
Found 20,595 articles
-
Antibe Closes Previously Announced Strategic Sale of Citagenix Subsidiary
11/2/2022
Antibe Therapeutics Inc is pleased to announce the closing of the sale of its Citagenix Inc. subsidiary to HANSAmed Limited (“HANSAmed”), a leading Canadian distributor of pharmaceuticals and medical devices to dental professionals.
-
Solesis Acquires Polyzen, Expanding Film and Coating Capabilities
11/2/2022
Polyzen, LLC, announced that it has been acquired by Solesis, an advanced biomaterials company that develops, manufactures, and sells critical components and technologies for customers in the medical device, biopharmaceutical, and life sciences industries.
-
Johnson & Johnson announced it was acquiring all outstanding shares of Abiomed for $16.6 billion to expand Abiomed's cardiovascular technologies and increase patient access.
-
H.I.G. Capital Completes Sale of Taconic Biosciences
11/1/2022
H.I.G. Capital (“H.I.G.”), a leading global alternative investment firm with $52 billion of equity capital under management, is pleased to announce the sale of its portfolio company Taconic Biosciences (“Taconic” or the “Company”) to Avista Capital Partners (“Avista”).
-
Citeline and Norstella Complete Merger to Form a $5 Billion Global Pharmaceutical Technology Company
11/1/2022
Norstella , a global leader with end-to-end solutions that smooth access to life-saving therapies for patients, has announced the completion of its merger with Citeline a leader in the clinical trial intelligence space.
-
Myriad Genetics Expands Consumer Access to Genetic Testing with Acquisition of Gateway Genomics and Its Market-Leading SneakPeek® Early Gender DNA Test
11/1/2022
Myriad Genetics, Inc., (NASDAQ: MYGN), a leader in genetic testing and precision medicine, today announced that it has acquired Gateway Genomics, LLC, a personal genomics company and developer of consumer genetic tests including the No. 1 selling SneakPeek® Early Gender DNA Test.
-
Ligand Distribution of OmniAb Complete and Business Combination Closed
11/1/2022
Ligand Pharmaceuticals Incorporated announced the completion of its expected tax-free distribution of 100% of Ligand’s interest in its subsidiary OmniAb on a pro rata basis to Ligand shareholders of record as of October 26, 2022.
-
Exelixis and Cybrexa Therapeutics Establish Exclusive Collaboration Providing Exelixis the Right to Acquire CBX-12, a Potential First-in-Class Peptide-Drug Conjugate of Exatecan
11/1/2022
Exelixis, Inc. and Cybrexa Therapeutics announced that the companies have entered into an exclusive collaboration agreement providing Exelixis the right to acquire CBX-12, a clinical-stage, first-in-class peptide-drug conjugate that utilizes Cybrexa’s proprietary alphalex technology to enhance delivery of exatecan to tumor cells.
-
Avista Capital Partners Acquires Taconic Biosciences
11/1/2022
Avista Capital Partners, a leading private equity firm focused exclusively on healthcare, announced its acquisition of Taconic Biosciences, a leading provider of genetically engineered research models and related services, from H.I.G. Capital.
-
RadNet Acquires a Controlling Interest in Heart & Lung Imaging Limited, a London-Based Teleradiology Network Focused on Lung Cancer Screening
11/1/2022
RadNet, Inc., a national leader in providing high-quality, cost-effective, fixed-site outpatient diagnostic imaging services, reported it has acquired a 75% interest in London-based Heart & Lung Imaging Limited.
-
OmniAb Announces Completion of Spin-Off and Business Combination
11/1/2022
OmniAb, Inc. announced the completion of the expected tax-free spin-off from Ligand Pharmaceuticals Incorporated and the subsequent business combination with Avista Public Acquisition Corp. II, resulting in OmniAb becoming an independent publicly traded company.
-
Intrinsic Medicine and Phoenix Biotech Acquisition Corp. Announce Merger Agreement to Create Public Company Leveraging Human Milk Biology to Treat Gut-Brain Axis Disorders
10/31/2022
Intrinsic Medicine, Inc. (Intrinsic), a therapeutics company leveraging human milk biology to transform Gut-Brain Axis (GBA) and inflammatory disorders, and Phoenix Biotech Acquisition Corp. (NASDAQ:PBAX) (PBAX), a special purpose acquisition company formed for the purpose of acquiring or merging with one or more businesses, today announced they have entered into a definitive business combination agreement.
-
Thermo Fisher Scientific to Acquire The Binding Site Group
10/31/2022
Thermo Fisher Scientific Inc. (NYSE: TMO) (“Thermo Fisher”), the world leader in serving science, today announced that it has entered into a definitive agreement to acquire The Binding Site Group (“The Binding Site”).
-
Coeptis Therapeutics, Inc. Announces Closing of Business Combination with Bull Horn Holdings Corp.
10/31/2022
Coeptis Therapeutics, Inc., a biopharmaceutical company developing innovative cell therapy platforms for cancer, announced the completion of its business combination with Bull Horn Holdings Corp., a special purpose acquisition company.
-
Struggling Bone Therapeutics may have caught a break. The cell therapy company is rebranding with the name BioSenic following a reverse merger with France’s Medsenic that closed Tuesday.
-
Aspen Surgical Acquires Symmetry Surgical
10/27/2022
Aspen Surgical Products, Inc. (“Aspen”), a portfolio company of Audax Private Equity (“Audax”) and a leader in disposable surgical products, announced the acquisition of Symmetry Surgical (“Symmetry”) from RoundTable Healthcare Partners. Symmetry represents Aspen’s 15th acquisition in total and sixth since Audax’ initial investment in Aspen in 2019.
-
Geistlich Pharma North America, Inc. acquires Lynch Biologics, LLC, a biologics and tissue engineering company
10/27/2022
Geistlich Pharma North America announced today the acquisition of Lynch Biologics, LLC, the developer and sole provider of GEM 21S®, the first recombinant growth factor product for use in oral regenerative surgery.
-
Agios and Sagard Healthcare Partners Announce $131.8 Million Purchase Agreement for TIBSOVO® Royalty
10/27/2022
Agios Pharmaceuticals, Inc. and Sagard Healthcare Partners announced that Agios has sold its rights to 5% royalties on U.S. net sales of Servier’s TIBSOVO® to Sagard for a one-time payment of $131.8 million.
-
GSK terminated its cell therapy pact with Lyell Immunopharma. It's opting to advance its own programs without use of Lyell’s T-cell modulating technologies that were at the center of the partnership.
-
Taysha Gene Therapies has entered into a strategic equity investment and licensing deal with Astellas. The latter stands to gain access to Taysha’s gene therapy development programs for Rett syndrome and GAN.